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Background: Emerging evidences indicate that dysregulated long non-coding RNAs (lncRNAs) are implicated in
cancer tumorigenesis and progression. LncRNA ANRIL has been shown to promote the progression of gastric
cancer. However, the role of lncRNA ANRIL in human non-small cell lung cancer (NSCLC) remains unclear.
Methods: Expression of lncRNA ANRIL was analyzed in 87 NSCLC tissues and three lung cancer cell lines by
quantitative real-time PCR (qRT-PCR). The correlation of lncRNA ANRIL with clinicopathological features and
prognosis was analyzed. Suppression of lncRNA ANRIL using siRNA treatment was performed in order to explore its
role in tumor progression.
Results: The expression level of lncRNA ANRIL was higher in NSCLC tissues and lung cancer cells than in adjacent
non-tumor tissues and normal human bronchial epithelial cells. Higher expression of lncRNA ANRIL in NSCLC tissues
was associated with higher TNM stage and advanced lymph node metastasis. Patients with high lncRNA ANRIL
expression had poorer overall survival compared with low lncRNA ANRIL group. Univariate and multivariate analyses
suggested that high expression of lncRNA ANRIL was an independent poor prognostic indicator for NSCLC patients.
Moreover, knockdown of lncRNA ANRIL expression could inhibit lung cancer cell proliferation, migration and invasion
in vitro.
Conclusions: Our results suggested that lncRNA ANRIL was a potential biomarker for NSCLC prognosis, and the
dysregulation of lncRNA ANRIL may play an important role in NSCLC progression.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1707061287149690.
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Lung cancer is one of the leading causes of all cancer-
related deaths worldwide, and with an incidence of over
200000 new cases every year [1]. Approximately, 85% of
all lung cancer cases are categorized as non-small cell
lung cancer (NSCLC), and more than 50% of NSCLC
patients have advanced local invasion and/or distant me-
tastases [2]. Despite much progress in early detection
and treatment, the 5-year survival rate for NSCLC pa-
tients at later stages is only 5-20% [3]. Therefore, it is
necessary for us to discover the underlying molecular* Correspondence: kejianc73@163.com
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article, unless otherwise stated.mechanisms and screen useful biomarkers and novel
therapeutic targets of NSCLC.
Traditionally, cancer was regarded as a genetic disease,
but current research revealed that cancer development
and progression involves epigenetic abnormalities [4].
Genetic continuity has been shown to involve epigenetic
regulation such as DNA methylation, histone deacetyla-
tion and non-coding RNA (ncRNA) regulation [5]. Long
non-coding RNAs (lncRNAs) are more than 200 nucleo-
tides in length with limited or no protein-coding cap-
acity and serve as the primary regulatory ncRNA [6].
Increasing evidences showed that lncRNAs could play
an important role in cellular development, differenti-
ation, and many other biological processes [7-9].distributed under the terms of the Creative Commons Attribution 4.0
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Table 1 Correlation between lncRNA ANRIL expression
and clinicopathological features in NSCLC patients
Parameters Group Total lncRNA ANRIL P value
Low High
Gender Male 51 23 28 0.952
Female 36 16 20
Age (years) <60 42 18 24 0.721
≥60 45 21 24
Tumor size (cm) <3 cm 39 16 23 0.520
≥3 cm 48 23 25




TNM stage I 26 19 7 0.001
II-III 61 20 41
Lymph node
metastasis
Absence 40 32 8 0.000
Presence 47 7 40
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core subunits SUZ12, EED and EZH2 and regulated
transcription by establishing di- and trimethylation of
histone H3 lysine 27 (H3K27me2 and H3K27me3), crit-
ical epigenetic silencing marks [10]. PRC2 target genes
played key roles in cell cycle regulation, stem cell self-
renewal and cell fate decisions and are frequently tar-
geted for epigenetic modulation in cancer [11]. Recent
studies showed that PRC2 could act as an oncogene or
tumor suppressor in tumors [12]. lncRNA ANRIL was
reported to have a direct role in recruiting PRC2 com-
plexes to specific loci and repress gene expression [13].
ANRIL (antisense non-coding RNA in the INK4
locus), a 3.8 kb lncRNA expressed in the opposite direc-
tion from INK4A-ARF-INK4B gene cluster [14]. Com-
mon disease genomewide association studies showed
ANRIL gene as a genetic susceptibility locus shared
associated by coronary disease, intracranial aneurysm,
type 2 diabetes and also cancers [15]. Yap et al. found
that lncRNA ANRIL was significantly up-regulated in
prostate cancer and involved in repressing of the p15/
CDKN2B-p16/CDKN2Ap14/ARF gene cluster in Cis by
directly binding to the PRC [16]. Zhang et al. showed
that lncRNA ANRIL was increased in gastric cancer and
associated with tumor size and advanced TNM stage.
Further experiments revealed that ANRIL knockdown
significantly repressed the proliferation both in vitro
and in vivo [17]. However, lncRNA ANRIL expres-
sion in NSCLC and the underlying mechanism is still
unknown.
In this study, the biological functions of lncRNA
ANRIL in NSCLC development were explored by exam-
ining the expression pattern of lncRNA ANRIL in
NSCLC tissues. Moreover, analysis of existent associ-
ation with both clinicopathological features and progno-
sis were examined in order to determine whether
lncRNA ANRIL could be considered a potential prog-
nostic factor for the prediction of clinical outcomes in
NSCLC patients. Finally, we conducted in vitro assay to




A total of 87 primary NSCLC patients were collected
from the Department of General Thoracic Surgery,
Shanghai Chest Hospital between 2004 and 2006. All pa-
tients did not receive chemotherapy or radiotherapy
prior to surgery. The clinicopathological findings were
determined according to the classification of malig-
nant tumors by the World Health Organization and
International Union against Cancer Tumor-Node-
Metastasis (TNM) staging system [18,19]. NSCLC tumor
tissues and their matched non-tumor tissues wereimmediately frozen in liquid nitrogen and stored at −70°C
until use. This study was approved by the Research
Ethics Committee of Shanghai Chest Hospital. Informed
consent was obtained from all of the patients. The clini-
copathological features of patients are summarized in
Table 1.
Cell culture and transfection
Three lung cancer cell lines (A549, SPC-A1, NCI-
H1650) and a normal human bronchial epithelial cell
line (16HBE) were purchased from the Institute of
Biochemistry and Cell Biology of the Chinese Academy of
Sciences (Shanghai, China). Cells were cultured in RPMI
1640 (Gibco) medium supplemented with 10% fetal bovine
serum (FBS), 100 U/ml penicillin, and 100 mg/ml strepto-
mycin in humidified air at 37°C with 5% CO2.
Lung cancer cells were transfected with either 50 nM
siRNAs targeting ANRIL (si-ANRIL) or scrambled nega-
tive controls (si-NC) (GenePharma) using the Lipofecta-
mine 2000 transfection reagent (Invitrogen) according to
the instructions provided by the manufacturer. The tar-
get sequence for ANRIL siRNAs was 5′-GGUCAUCU
CAUUGCUCUAU-3′ [13]. After 24 h, knockdown of
ANRIL was confirmed via qRT-PCR.
Cell proliferation assay
The in vitro cell proliferation of lung cancer cells was
measured using the MTT method. In brief, cells were
seeded into 96-well plates and transfected with 50 nM
si-ANRIL or si-NC for 24 h. In the indicated time
periods, 0.1 ml of spent medium was replaced with
an equal volume of fresh medium containing MTT
0.5 mg/ml. Plates were incubated at 37°C for 4 hours,
and then the medium was replaced with 0.1 ml of
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temperature for 10 min. The absorbance was mea-
sured at 490 nm using an enzyme-labeled analyzer.
Cell migration and invasion assays
Lung cancer cells were transfected with 50 nM si-ANRIL
or si-NC. After 24 h, transfected cells were harvested. In
migration assay, transfected cells (1x105) were plated in
the top chamber of Transwell assay inserts (Millipore)
with a membrane containing pores with 8 mm diameters
in 200 ml of serum-free RPMI1640. Assays were con-
ducted in triplicate. Inserts were then placed into the
bottom chamber wells of a 24-well plate containing
RPMI1640 with 10% FBS as a chemoattractant. After 24 h
of incubation, remaining cells were removed from the top
layer of the insert by scrubbing with a sterile cotton swab.
Invading cells from the bottom surface were stained with
0.1% crystal violet prior to being examined, counted and
photographed using digital microscopy. Cell numbers
were calculated in five random fields for each chamber,
and the average value was calculated. In invasion
assay, transfected cells (4x105) were plated in the top
chamber with a Matrigel-coated membrane. Bottom
chambers were filled with conditioned medium. After
a 48 h incubation period, the number of migrated
cells on the lower side of the membrane was counted
as described previously.
Quantitative realtime PCR (qRT-PCR)
Total RNA was extracted from tissues or cultured cells
using TRIzol reagent (Invitrogen). For qRT-PCR, RNA
was reverse transcribed to cDNA by using a Reverse
Transcription Kit (Takara). Real-time PCR analyses were
performed with Power SYBR Green (Takara). Results
were normalized to the expression of GAPDH. The PCR
primers for ANRIL or GAPDH were as follows: ANRIL




PCR and data collection were performed on ABI 7900.
The relative expression of ANRIL was calculated and
normalized using the 2-ΔΔCt method relative to GAPDH.
Statistical analysis
All statistical analyses were performed using SPSS ver-
sion 18.0 software (IBM). Comparison of continuous
data was analyzed using an independent t-test between
the two groups, whereas categorical data was analyzed
by the chi-square test. Overall survival curves were plot-
ted according to the Kaplan-Meier method, with the
log-rank test applied for comparison. A Cox propor-
tional hazards regression analysis was used for univariate
and multivariate analyses of prognostic values. The dataare shown as the mean ± SD from at least three inde-
pendent experiments. Values of P less than 0.05 were
considered statistically significant.
Results
LncRNA ANRIL was up-regulated in NSCLC tissues
qRT-PCR assay was performed to detect the expression
of lncRNA ANRIL in 87 NSCLC tissues and correspond-
ing non-tumor tissues. As shown in Figure 1A, the rela-
tive level of lncRNA ANRIL expression was significantly
higher in NSCLC tissues than in adjacent non-tumor tis-
sues (P < 0.05). To assess the correlation of lncRNA
ANRIL expression with clinicopathologic features, ac-
cording to the mean value of relative lncRNA ANRIL
expression (3.6) in tumor tissues, the 87 NSCLC patients
were classified into two groups: relative high-ANRIL
group: ANRIL expression ratio ≥mean; relative low-
ANRIL group: ANRIL expression ratio <mean (Figure 1B).
As shown in Table 1, the expression of lncRNA ANRIL
was significantly correlated with TNM stage and lymph
node metastasis (P < 0.05). However, there were no signifi-
cant correlations between lncRNA ANRIL expression and
other clinicopathologic features including patient’s gender,
age, tumor size and histology (P > 0.05). Taken together,
these observations suggested that increased lncRNA
ANRIL expression was associated with the progression and
development of NSCLC.
Over-expression of lncRNA ANRIL was associated with
poor prognosis of NSCLC
Kaplan-Meier analysis and log-rank test were used to
evaluate the effects of lncRNA ANRIL expression and
the clinicopathological features on overall survival of
NSCLC patients. As shown in Figure 1C, the overall sur-
vival of patients with high lncRNA ANRIL expression
was significantly poor than that of those with low
lncRNA ANRIL expression (P < 0.05). Univariate analysis
showed that TNM stage, lymph node metastasis and
lncRNA ANRIL expression were significantly correlated
with poor overall survival of NSCLC patients (P < 0.05;
Table 2). Multivariate analysis suggested that relative
lncRNA ANRIL expression level, TNM stage and lymph
node metastasis were independent prognostic indicators
for the overall survival of NSCLC patients (Table 2).
These results revealed that lncRNA ANRIL expression
could develop as a powerful independent factor for pre-
dicting the prognosis of NSCLC patients.
lncRNA ANRIL expression in lung cancer cells and lung
cancer cell transfection
To investigate the roles of lncRNA ANRIL in NSCLC,
we performed qRT-PCR to evaluate the levels of ANRIL
in three NSCLC cell lines and one normal human bron-
chial epithelial cell line (16HBE). The expression of
Figure 1 Relative lncRNA ANRIL expression and its clinical significance in NSCLC patients. A. Relative expression of lncRNA ANRIL in NSCLC
tissues in comparison with adjacent non-tumor tissues. lncRNA ANRIL expression was examined by qRT-PCR and normalized to GAPDH expression.
B. The 87 total NSCLC patients included in the study were divided into an relative high-ANRIL group (n = 48) and relative low-ANRIL group (n = 39)
according to the mean value of relative lncRNA ANRIL expression. C. Kaplan-Meier overall survival curves according to lncRNA ANRIL expression
level. Results are expressed as mean ± SD for three replicate determination. * P <0.05.
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pared with the levels observed in 16HBE cells, with the
highest in SPC-A1 cells (Figure 2A). Thus SPC-A1 cells
were selected and transfected with si-ANRIL or si-NC.
Our results showed that lncRNA ANRIL expression was
effectively knocked down in SPC-A1 cells (Figure 2B).Knockdown lncRNA ANRIL suppressed lung cancer cell
growth and metastasis
We investigated the impact of lncRNA ANRIL on the
growth of lung cancer cells, MTT assay showed that the
proliferation rate of of SPC-A1 cells transfected with si-
ANRIL was significantly decreased compared with the
Table 2 Univariate and multivariate analysis of prognostic parameters in NSCLC patients by Cox regression analysis
Variable Univariate analysis Multivariate analysis
Risk ratio 95% CI P-value Risk ratio 95% CI P-value
Gender 1.328 0.653-2.344 0.552
Male vs female
Age (years) 1.817 0.726-3.408 0.472
≥60 vs <60
Tumor size 1.533 0.874-1.912 0.764
≥3 cm vs <3 cm
Histologic grade 0.892 0.531-1.275 0.318
Squamous cell carcinoma vs adenocarcinoma
TNM stage 2.936 1.526-5.712 0.007 2.517 1.368-5.215 0.011
II-III vs I
Lymph node metastasis 3.371 1.484-6.933 <0.001 2.868 1.392-6.173 0.006
Presence vs absence
lncRNA ANRIL 2.793 1.425-5.791 0.002 2.538 1.374-5.452 <0.001
High vs low
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gration and invasion assays were used to examine the ef-
fect of lncRNA ANRIL on lung cancer cell metastasis.
Transwell migration assay showed that the migration
ability of SPC-A1 cells transfected with si-ANRIL was
significantly decreased compared with the si-NC group
(P < 0.05, Figure 3B). Transwell invasion assay revealed
that the invasion capacity of SPC-A1 cells transfected
with si-ANRIL was notably down-regulated compared to
si-NC group (P < 0.05, Figure 3C). These results sug-
gested that lncRNA ANRIL could promote the growth
and metastasis of lung cancer cells.
Discussion
The sequencing of the human genome revealed that the
coding portion of the genome represents less than 2%
of the genome. The remaining 98% of transcription
products of the genome consists of non-coding RNAFigure 2 Relative lncRNA ANRIL expression level in lung cancer cells.
(A549, SPC-A1, NCI-H1650) compared with the normal bronchial epithelial
following treatment of SPC-A1 cells with si-ANRIL or si-NC by qRT-PCR. Res
* P <0.05.sequences, including microRNAs and lncRNAs [20]. Re-
cently, numerous pieces of evidence showed that dysreg-
ulation in lncRNAs are proved to contribute in tumor
development in many cancer types and can be used to
develop as biomarkers and therapy target [21]. For ex-
ample, Zhang et al. demonstrated that lncRNA SPRY4-
IT1 (SPRY4 intronic transcript 1) was increased in clear
cell renal cell carcinoma (ccRCC) tissues and ccRCC
patients with higher SPRY4-IT1 expression had an ad-
vanced clinical stage and poorer prognosis [22]. Wang
et al. showed that lncRNA PlncRNA-1 was significantly
higher in human esophageal squamous cell carcinoma
and correlated with advanced clinical stage and lymph
node metastasis. Knockdown of PlncRNA-1 reduced cell
proliferation and increased the apoptosis in vitro [23].
Sun et al. found that GAS5 (Growth arrest-specific 5)
expression was markedly down-regulated in gastric can-
cer and associated poorer disease-free survival andA. Analysis of lncRNA ANRIL expression levels in NSCLC cell lines
cell line (16HBE) by qRT-PCR. B. Analysis of lncRNA ANRIL expression
ults are expressed as mean ± SD for three replicate determination.
Figure 3 Down-regulation of lncRNA ANRIL promotes lung cancer cell proliferation, migration and invasion. A. MTT assay was performed
to determine the proliferation of si-ANRIL transfected SPC-A1 cells. B. Transwell migration assay was used to investigate the migration of si-ANRIL
transfected SPC-A1 cells. C. Transwell invasion assay was performed to investigate the invasion of si-ANRIL transfected SPC-A1 cells. Results are
expressed as mean ± SD for three replicate determination. * P <0.05.
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topic expression of GAS5 was demonstrated to decrease
gastric cancer cell proliferation and induce apoptosis
in vitro and in vivo [24]. However, the expression profile
and potential function of lncRNA ANRIL in NSCLC is
still unknown.
In the study, we explored the clinical significance of
lncRNA ANRIL in NSCLC patients for the first time. By
using qRT-PCR, we found that lncRNA ANRIL was in-
creased in NSCLC tissues and lung cancer cell lines to a
greater extent than in adjacent non-tumor tissues and
normal human bronchial epithelial cell line. We also re-
vealed that the relative expression level of lncRNA
ANRIL was associated with TNM stage and lymph node
metastasis of NSCLC patients. These findings suggested
that a higher level of lncRNA ANRIL expression may be
involved in NSCLC pathogenesis and progression.
Furthermore, we analyzed a correlation between lncRNA
ANRIL expression level and prognosis of NSCLC. Our
results showed patients with high lncRNA ANRIL ex-
pression had a shorter overall survival rate than those
with low lncRNA ANRIL group. These findings were
further supported by the univariate and multivariate
analyses of Cox proportional hazards regression model,
indicating that the expression of lncRNA ANRIL could
be an independent factor for predicting the prognosis
of NSCLC patients. Therefore, our data demonstrated
that increased expression of lncRNA ANRIL was asso-
ciated with an high risk of death from NSCLC. Then,
we analyzed the effect of lncRNA ANRIL expression on
the growth and metastasis of lung cancer cells. We
found that down-regulated expression of lncRNA ANRIL
significantly decreased proliferation, migration and inva-
sion capability of lung cancer cells in vitro. These data fur-
ther support the importance of ANRIL in cellular biology
and oncogenesis of lung cancer cells and indicate that
ANRIL is involved in the development and progression of
NSCLC.Conclusion
In summary, our study demonstrated that the expression
level of lncRNA ANRIL was increased in NSCLC tissues
compared to that in the adjacent non-tumor tissues. Ele-
vated lncRNA ANRIL expression has been associated
with poor prognosis of overall survival, likely due to the
ability of lncRNA ANRIL to promote cell growth and
metastasis in lung cancer cells. These results indicated
that lncRNA ANRIL played a critical role in the progres-
sion of NSCLC. The development of ANRIL-based
therapeutic strategies for the downregulation of such
oncogenic lncRNAs may provide a novel and promis-
ing alternative therapeutic approach for future cancer
treatment.
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